What’s Now and What’s Next: A look at the year in review for clinical research, biotech, life sciences and pharma
The role of drug companies, patients, and physicians in bringing drugs to market, clinical trial sites, and clinical research have all shifted significantly this year. But what’s really changed and what’s in store for next year?
In our Towards Health podcast, we were joined by industry veterans, Brad Hightower and Darshan Kulkarni. Learn a little more about Brad and Darshan as we discuss “From PIs to PharmD’s – 2022 Pharma Year in Review.”
About our guests:
Brad Hightower, CCRC, is the founder of Hightower Clinical Trial Services and the host of the Note to File Podcast.
Darshan Kulkarni, PharmD, MS, Esq. is a Life Science Entrepreneur and Counsel, host of the Darshantalks Livestream podcast, Educator, Board Member, Speaker, and Author.
Both Darshan and Brad are considered industry experts and influencers. In this episode, we talk about:
- The year’s biggest challenges and wins
- Pharma’s “AHA” moments of this year
- Where the economic downturn will impact the industry
- Where data or technology innovation has had the great impact and whether the FDA’s recent diversity guidelines will actually help or hinder health equity
- Predictions for 2023